Next Article in Journal
Malignancies Associated with Extraovarian Endometriosis: A Literature Review
Previous Article in Journal
Nutrition, Exercise, and Stress Management for Treatment and Prevention of Psychiatric Disorders. A Narrative Review Psychoneuroendocrineimmunology-Based
Article

The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly

1
Neuroendocrinology Unit, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), 28034 Madrid, Spain
2
Endocrinology Unit, Department of Pathology Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
3
Neuroendocrinology Unit, Department of Neurosurgery, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
4
Endoscopic Skull Base Unit, Department of Neurosurgery, Hospital Universitario HM Puerta del Sur, 28938 Madrid, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Antonio Brunetti
Received: 1 July 2021 / Revised: 28 July 2021 / Accepted: 3 August 2021 / Published: 5 August 2021
(This article belongs to the Section Neuroendocrinology and Pituitary Disorders)
Purpose: to determine whether pre-surgical treatment using long-acting somatostatin analogues (SSAs) may improve surgical outcomes in acromegaly. Methods: retrospective study of 48 patients with acromegaly operated by endoscopic transsphenoidal approach and for first time. Surgical remission was evaluated based on the 2010 criteria. Results: most patients, 83.3% (n = 40), harbored macroadenomas and 31.3% (n = 15) invasive pituitary adenomas. In this case, 14 patients were treated with lanreotide LAR and 6 with octreotide LAR, median monthly doses of 97.5 [range 60–120] and 20 [range 20–30] mg, respectively, for at least 3 months preoperatively. Presurgical variables were comparable between pre-treated and untreated patients (p > 0.05). Surgical remission was more frequent in those pre-treated with monthly doses ≥90 mg of lanreotide or ≥30 mg of octreotide than in untreated or pre-treated with lower doses (OR = 4.64, p = 0.025). However, no differences were found between pre-treated and untreated patients when lower doses were included or between those treated for longer than 6 months compared to those untreated or pre-treated for shorter than 6 months. Similarly, no differences were found either in terms of surgical or endocrine complications (OR = 0.65, p = 0.570), independently of the doses and the duration of SSA treatment (p > 0.05). Conclusions: the dose of SSAs is a key factor during pre-surgical treatment, since the beneficial effects in surgical remission were observed with monthly doses equal or higher than 90 mg of lanreotide and 30 mg of octreotide, but not with lower doses. View Full-Text
Keywords: acromegaly; somatostatin analogues; presurgical treatment; surgical remission acromegaly; somatostatin analogues; presurgical treatment; surgical remission
Show Figures

Figure 1

MDPI and ACS Style

Araujo-Castro, M.; Pascual-Corrales, E.; Pian, H.; Ruz-Caracuel, I.; Acitores Cancela, A.; Duque, S.G.; Berrocal, V.R. The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly. Endocrines 2021, 2, 241-250. https://0-doi-org.brum.beds.ac.uk/10.3390/endocrines2030023

AMA Style

Araujo-Castro M, Pascual-Corrales E, Pian H, Ruz-Caracuel I, Acitores Cancela A, Duque SG, Berrocal VR. The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly. Endocrines. 2021; 2(3):241-250. https://0-doi-org.brum.beds.ac.uk/10.3390/endocrines2030023

Chicago/Turabian Style

Araujo-Castro, Marta, Eider Pascual-Corrales, Héctor Pian, Ignacio Ruz-Caracuel, Alberto Acitores Cancela, Sara G. Duque, and Víctor R. Berrocal 2021. "The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly" Endocrines 2, no. 3: 241-250. https://0-doi-org.brum.beds.ac.uk/10.3390/endocrines2030023

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop